The global companion animal osteoarthritis market was valued at USD 3.0 billion in 2025 and is expected to expand from USD 3.4 billion in 2026 to USD 5.2 billion by 2033, registering a CAGR of 6.5% from 2026 to 2033. North America led the market in 2025, accounting for 40.0% of global revenue.

Market expansion is being supported by advances in veterinary treatments, rising pet ownership expenditure, the growing humanization of companion animals, supportive veterinary programs and initiatives, and demographic changes among pets worldwide.

What Is Driving Market Growth?

Greater Investment in Pet Healthcare

The humanization of pets is encouraging owners to treat companion animals as family members and spend more on chronic-condition management. As a result, demand is increasing for specialized osteoarthritis therapies, long-term pain management, veterinary consultations, and mobility-support solutions.

Aging Companion Animal Population

Longer pet lifespans are contributing to a higher incidence of age-associated conditions, including osteoarthritis. The growing population of senior dogs and cats is consequently creating sustained demand for therapies designed to manage chronic joint pain, inflammation, and mobility limitations.

Progress in Veterinary Treatment

Advances in veterinary medicine are making osteoarthritis management increasingly targeted and effective. Pharmaceutical therapies, biologics, regenerative medicine, and non-pharmaceutical interventions are expanding the range of treatment options available to veterinarians and pet owners.

Regenerative approaches such as stem cell therapy and platelet-rich plasma (PRP) have attracted increasing attention because of their potential to reduce inflammation and support joint healing. According to an American Veterinary Medical Association article published in February 2024, developments in regenerative medicine have contributed to improvements in the management of joint conditions such as osteoarthritis, including pain and mobility management.

Precision medicine is another emerging area. By tailoring treatment approaches to the characteristics and needs of individual animals, veterinarians can increasingly pursue more personalized osteoarthritis-management strategies.

Download a free sample report or claim your copy of this full market intelligence report

Segment and Regional Highlights

Canine animals remain the core market segment, accounting for 59.5% of the market in 2025, while the feline segment is expected to experience faster growth as awareness of osteoarthritis in cats increases.

Biologics led the product landscape with a 40.1% share in 2025. The segment is benefiting from continuing innovation in advanced veterinary therapeutics, including antibody-based and regenerative approaches.

Oral therapies dominated administration routes, representing 59.0% of the market in 2025. Injectable treatments, however, are gaining attention as advanced biologics and other veterinary therapies become more widely adopted.

Veterinary hospitals and clinics represented the leading distribution channel, reflecting the importance of professional diagnosis, treatment selection, monitoring, and long-term disease management.

North America remained the largest regional market in 2025 with a 40.0% revenue share. Meanwhile, Asia Pacific is projected to record the fastest growth from 2026 to 2033, supported by evolving pet-care practices, increasing veterinary healthcare expenditure, and greater awareness of companion-animal diseases.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Competitive Landscape

The companion animal osteoarthritis market includes established animal-health and veterinary pharmaceutical companies developing and commercializing treatments for pain, inflammation, mobility impairment, and chronic joint disease.

Key companies include:

• Zoetis Inc.
• Boehringer Ingelheim
• Elanco Animal Health
• American Regent, Inc.
• Merck Animal Health (Merck & Co. Inc.)
• Vetoquinol S.A.
• Ceva Santé Animale
• Virbac
• Biogenesis Bago
• Ardent Animal Health, LLC

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

• S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.